Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

NEW YORK, NY / ACCESS Newswire / January 28, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

The Danish drug giant Novo Nordisk, known for its antidiabetes and weight loss drugs such as semaglutide (Ozempic or Wegovy), ...

Growing demand for weight-loss solutions has catapulted pharmaceutical firms like Eli Lilly (LLY) and Novo Nordisk (NVO) into ...

A multi-million dollar Super Bowl ad from telehealth company Hims and Hers downplays risks and side effects of compounded ...

Ozempic, the drug that was originally approved to treat type 2 diabetes, has now also been approved by the FDA to reduce ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...